Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky

Jack Stone,Hannah Fraser,April M Young,Jennifer R Havens,Peter Vickerman

doi:10.1016/j.drugpo.2020.102707

Jack Stone, Hannah Fraser + Show 3 more

Open Access

https://doi.org/10.1016/j.drugpo.2020.102707

Copy DOI

Abstract

BackgroundPeople who inject drugs (PWID) experience high incarceration rates, with current/recent incarceration being associated with increased hepatitis C virus (HCV) transmission. We assess the contribution of incarceration to HCV transmission amongst PWID in Perry County (PC), Kentucky, USA, and the impact of scaling-up community and in-prison opioid substitution therapy (OST), including the potential for reducing incarceration.MethodsA dynamic model of incarceration and HCV transmission amongst PWID was calibrated in a Bayesian framework to epidemiological and incarceration data from PC, incorporating an empirically estimated 2.8-fold (95%CI: 1.36–5.77) elevated HCV acquisition risk amongst currently incarcerated or recently released (<6 months) PWID compared to other PWID. We projected the percentage of new HCV infections that would be prevented among PWID over 2020–2030 if incarceration no longer elevated HCV transmission risk, if needle and syringe programmes (NSP) and OST are scaled-up, and/or if drug use was decriminalized (incarceration/re-incarceration rates are halved) with 50% of PWID that would have been imprisoned being diverted onto OST. We assume OST reduces reincarceration by 10–42%.ResultsOver 2020–2030, removing the effect of incarceration on HCV transmission could prevent 42.7% (95% credibility interval: 15.0–67.4%) of new HCV infections amongst PWID. Conversely, scaling-up community OST and NSP to 50% coverage could prevent 28.5% (20.0–37.4%) of new infections, with this increasing to 32.7% (24.5–41.2%) if PWID are retained on OST upon incarceration, 36.4% (27.7–44.9%) if PWID initiate OST in prison, and 45.3% (35.9–54.1%) if PWID are retained on OST upon release. decriminalization (with diversion to OST) could further increase this impact, preventing 56.8% (45.3–64.5%) of new infections. The impact of these OST interventions decreases by 2.1–28.6% if OST does not reduce incarceration.ConclusionIncarceration is likely to be an important contributor to HCV transmission amongst PWID in PC. Prison-based OST could be an important intervention for reducing this risk.

Highlights

The U.S has the largest global prison population [2,121,600](1) and one of the largest populations of people who inject drugs (PWID, estimated 2,248,500)(2)
We projected the percentage of new hepatitis C virus (HCV) infections that would be prevented among People who inject drugs (PWID) over 2020-2030 if incarceration no longer elevated HCV transmission risk, if needle and syringe programmes (NSP) and opioid substitution therapy (OST) are scaled-up, and/or if drug use was decriminalised with 50% of PWID that would have been imprisoned being diverted onto OST
Scaling-up community OST and NSP to 50% coverage could prevent 28.5% (20.0-37.4%) of new infections, with this increasing to 32.7% (24.5-41.2%) if PWID are retained on OST upon incarceration, 36.4% (27.7-44.9%) if PWID initiate OST in prison, and 45.3% (35.9-54.1%) if PWID are retained on OST upon release

Summary

Introduction

The U.S has the largest global prison population [2,121,600](1) and one of the largest populations of people who inject drugs (PWID, estimated 2,248,500)(2). PWID have a high HCV sero-prevalence in the U.S, with most new HCV infections occurring within this group[4]. An epidemic of prescription opioid abuse in rural regions of the U.S(5) led to an increase in the number of PWID[6] and an upsurge in reported cases of acute HCV infection[7]. People who inject drugs (PWID) experience high incarceration rates, with current/recent incarceration being associated with increased hepatitis C virus (HCV) transmission. We assess the contribution of incarceration to HCV transmission amongst PWID in Perry County (PC), Kentucky, USA, and the impact of scaling-up community and in-prison opioid substitution therapy (OST), including the potential for reducing incarceration

Methods

Results

Conclusion